TCR2 THERAPEUTICS INC.
DelistedCIK 1750019fmd_14WGCS5431M51X5JJR4Y22AV9HManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2018 to Mar 31, 2023, 21 periods
Latest annual · FY2022
Millions- Operating income
- (153)
- Net income
- (152)
- Free cash flow
- (117)
Latest quarter · Q1 FY2023
Millions- Operating income
- (42)
- Net income
- (40)
- Free cash flow
- (40)
TCR2 THERAPEUTICS INC. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2022 | FY2021 | Change | Source |
|---|---|---|---|---|
| Operating income | -$153.5 million | -$99.7 million | 10-K 2023-03-23 · proof | |
| Net income | -$151.8 million | -$99.8 million | 10-K 2023-03-23 · proof | |
| Cash from operating activities | -$101.5 million | -$81.6 million | 10-K 2023-03-23 · proof | |
| Free cash flow | -$116.6 million | -$92.7 million | 10-K 2023-03-23 · proof | |
| Total assets | $208.2 million | $323.4 million | -35.6% | 10-K 2023-03-23 · proof |
| Total liabilities | $67.4 million | $41.9 million | +60.8% | 10-K 2023-03-23 · proof |
| Cash and cash equivalents | $32.7 million | $222.6 million | -85.3% | 10-K 2023-03-23 · proof |
- What was TCR2 THERAPEUTICS INC.'s operating income in fiscal 2022?
- TCR2 THERAPEUTICS INC. reported operating income of -$153.5 million for fiscal 2022 (the year ended Dec 31, 2022), against -$99.7 million the year before. Source: the 10-K filed with the SEC on Mar 23, 2023. SEC
- What was TCR2 THERAPEUTICS INC.'s net income in fiscal 2022?
- TCR2 THERAPEUTICS INC. reported net income of -$151.8 million for fiscal 2022 (the year ended Dec 31, 2022), against -$99.8 million the year before. Source: the 10-K filed with the SEC on Mar 23, 2023. SEC
- What was TCR2 THERAPEUTICS INC.'s cash from operating activities in fiscal 2022?
- TCR2 THERAPEUTICS INC. reported cash from operating activities of -$101.5 million for fiscal 2022 (the year ended Dec 31, 2022), against -$81.6 million the year before. Source: the 10-K filed with the SEC on Mar 23, 2023. SEC
- What was TCR2 THERAPEUTICS INC.'s free cash flow in fiscal 2022?
- TCR2 THERAPEUTICS INC. reported free cash flow of -$116.6 million for fiscal 2022 (the year ended Dec 31, 2022), against -$92.7 million the year before. Source: the 10-K filed with the SEC on Mar 23, 2023. SEC
- What are TCR2 THERAPEUTICS INC.'s total assets?
- As of Dec 31, 2022, TCR2 THERAPEUTICS INC. reported total assets of $208.2 million, against $323.4 million a year earlier (-35.6%). Source: the 10-K filed with the SEC on Mar 23, 2023. SEC
- What are TCR2 THERAPEUTICS INC.'s total liabilities?
- As of Dec 31, 2022, TCR2 THERAPEUTICS INC. reported total liabilities of $67.4 million, against $41.9 million a year earlier (+60.8%). Source: the 10-K filed with the SEC on Mar 23, 2023. SEC
- What are TCR2 THERAPEUTICS INC.'s cash and cash equivalents?
- As of Dec 31, 2022, TCR2 THERAPEUTICS INC. reported cash and cash equivalents of $32.7 million, against $222.6 million a year earlier (-85.3%). Source: the 10-K filed with the SEC on Mar 23, 2023. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1750019&period_type=annual&limit=5"Information only, not investment advice.